A Phase 2, Observer-Blind, Placebo-Controlled, Proof-of-concept Trial to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus Vaccine in Liver Transplant Candidates and Recipients

Grants and Contracts Details

StatusActive
Effective start/end date3/25/246/25/24

Funding

  • ModernaTX Incorporated: $9,983.00